 Neil Aggarwal
Concepts (306)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Outpatients | 5 | 2024 | 393 | 2.080 |
Why?
| | Oxygen | 8 | 2024 | 943 | 1.710 |
Why?
| | Acute Lung Injury | 11 | 2015 | 288 | 1.280 |
Why?
| | Macrophages, Alveolar | 5 | 2016 | 392 | 1.220 |
Why?
| | Pneumonia | 7 | 2025 | 638 | 1.050 |
Why?
| | Antiviral Agents | 4 | 2024 | 740 | 0.990 |
Why?
| | T-Lymphocytes, Regulatory | 5 | 2015 | 392 | 0.850 |
Why?
| | Hospitalization | 7 | 2024 | 2197 | 0.820 |
Why?
| | Interleukin-6 | 2 | 2024 | 778 | 0.720 |
Why?
| | National Heart, Lung, and Blood Institute (U.S.) | 6 | 2021 | 104 | 0.710 |
Why?
| | Oxygen Inhalation Therapy | 3 | 2024 | 160 | 0.690 |
Why?
| | Positive-Pressure Respiration | 1 | 2018 | 80 | 0.560 |
Why?
| | Phagocytes | 1 | 2018 | 100 | 0.540 |
Why?
| | Smoke | 1 | 2016 | 144 | 0.460 |
Why?
| | Leukocytes, Mononuclear | 1 | 2018 | 558 | 0.460 |
Why?
| | Lung | 12 | 2018 | 4066 | 0.460 |
Why?
| | Receptor, Adenosine A2A | 1 | 2013 | 20 | 0.410 |
Why?
| | Lipopolysaccharides | 9 | 2015 | 886 | 0.380 |
Why?
| | Antibodies, Viral | 3 | 2024 | 623 | 0.370 |
Why?
| | Immunity, Innate | 1 | 2018 | 832 | 0.370 |
Why?
| | Adult | 21 | 2025 | 37821 | 0.350 |
Why?
| | Antibodies, Monoclonal | 5 | 2024 | 1428 | 0.350 |
Why?
| | Lung Injury | 2 | 2011 | 218 | 0.340 |
Why?
| | Hydroxychloroquine | 2 | 2020 | 59 | 0.340 |
Why?
| | Critical Illness | 5 | 2025 | 809 | 0.340 |
Why?
| | Mice, Inbred C57BL | 16 | 2025 | 5792 | 0.330 |
Why?
| | Bacteria | 1 | 2016 | 858 | 0.320 |
Why?
| | Hypoxia | 4 | 2024 | 1108 | 0.310 |
Why?
| | Research Report | 2 | 2021 | 83 | 0.310 |
Why?
| | Smoking | 2 | 2016 | 1639 | 0.310 |
Why?
| | Respiratory Insufficiency | 2 | 2023 | 316 | 0.310 |
Why?
| | Intensive Care Units | 3 | 2025 | 803 | 0.300 |
Why?
| | Macrophages | 1 | 2016 | 1548 | 0.290 |
Why?
| | Bronchoalveolar Lavage Fluid | 7 | 2013 | 654 | 0.290 |
Why?
| | Flow Cytometry | 3 | 2018 | 1185 | 0.280 |
Why?
| | Humans | 44 | 2025 | 137514 | 0.280 |
Why?
| | Epithelial Cells | 4 | 2016 | 1099 | 0.270 |
Why?
| | Inflammation Mediators | 4 | 2016 | 514 | 0.270 |
Why?
| | Vaccination | 2 | 2024 | 1398 | 0.270 |
Why?
| | Wound Healing | 1 | 2009 | 327 | 0.270 |
Why?
| | Mice | 15 | 2025 | 17843 | 0.260 |
Why?
| | Critical Care | 2 | 2024 | 584 | 0.260 |
Why?
| | Mice, Knockout | 8 | 2015 | 3020 | 0.250 |
Why?
| | Carotid Artery, Internal | 1 | 2006 | 42 | 0.250 |
Why?
| | Male | 29 | 2025 | 67718 | 0.250 |
Why?
| | Immunophenotyping | 2 | 2018 | 321 | 0.240 |
Why?
| | Carotid Artery Diseases | 1 | 2006 | 66 | 0.240 |
Why?
| | Sepsis | 2 | 2024 | 611 | 0.240 |
Why?
| | Aged | 14 | 2025 | 23798 | 0.230 |
Why?
| | Phagocytosis | 2 | 2018 | 379 | 0.230 |
Why?
| | Intracranial Aneurysm | 1 | 2006 | 97 | 0.230 |
Why?
| | Lymphopenia | 1 | 2025 | 61 | 0.230 |
Why?
| | Animals | 19 | 2025 | 37011 | 0.230 |
Why?
| | Organ Dysfunction Scores | 1 | 2024 | 47 | 0.220 |
Why?
| | Health Care Rationing | 1 | 2024 | 60 | 0.220 |
Why?
| | Adenosine Monophosphate | 1 | 2024 | 66 | 0.220 |
Why?
| | Respiration, Artificial | 3 | 2024 | 643 | 0.210 |
Why?
| | Lung Diseases | 2 | 2021 | 768 | 0.210 |
Why?
| | Multiple Organ Failure | 1 | 2024 | 127 | 0.210 |
Why?
| | Alanine | 1 | 2024 | 153 | 0.210 |
Why?
| | Antigens, Viral | 1 | 2024 | 180 | 0.210 |
Why?
| | Noninvasive Ventilation | 1 | 2024 | 51 | 0.210 |
Why?
| | Antibodies, Neutralizing | 2 | 2022 | 282 | 0.210 |
Why?
| | Biomedical Research | 2 | 2021 | 689 | 0.210 |
Why?
| | Analgesics, Non-Narcotic | 1 | 2024 | 126 | 0.200 |
Why?
| | Middle Aged | 14 | 2025 | 33355 | 0.200 |
Why?
| | Sleep Deprivation | 1 | 2025 | 174 | 0.200 |
Why?
| | Public-Private Sector Partnerships | 2 | 2021 | 43 | 0.200 |
Why?
| | Gene Expression Profiling | 1 | 2009 | 1770 | 0.200 |
Why?
| | Ritonavir | 1 | 2023 | 73 | 0.190 |
Why?
| | Pulmonary Circulation | 2 | 2021 | 430 | 0.190 |
Why?
| | Polycystic Kidney, Autosomal Dominant | 1 | 2006 | 260 | 0.190 |
Why?
| | Intubation, Intratracheal | 1 | 2024 | 259 | 0.190 |
Why?
| | Acetaminophen | 1 | 2024 | 269 | 0.180 |
Why?
| | Cytokines | 3 | 2016 | 2095 | 0.180 |
Why?
| | Cell Membrane Permeability | 2 | 2012 | 82 | 0.180 |
Why?
| | Education | 1 | 2021 | 108 | 0.170 |
Why?
| | RNA, Viral | 1 | 2024 | 653 | 0.170 |
Why?
| | Pulmonary Alveoli | 3 | 2015 | 405 | 0.160 |
Why?
| | Tidal Volume | 2 | 2018 | 86 | 0.160 |
Why?
| | Neutrophils | 4 | 2015 | 1238 | 0.160 |
Why?
| | Triglycerides | 2 | 2013 | 525 | 0.160 |
Why?
| | Antibodies | 1 | 2021 | 414 | 0.160 |
Why?
| | Disease Models, Animal | 6 | 2025 | 4295 | 0.150 |
Why?
| | Financing, Government | 1 | 2019 | 46 | 0.150 |
Why?
| | Machine Learning | 1 | 2024 | 496 | 0.150 |
Why?
| | Serum Bactericidal Test | 1 | 2018 | 1 | 0.150 |
Why?
| | Ventricular Function, Right | 1 | 2021 | 283 | 0.150 |
Why?
| | Rare Diseases | 1 | 2019 | 101 | 0.150 |
Why?
| | Interinstitutional Relations | 1 | 2018 | 54 | 0.150 |
Why?
| | Partial Pressure | 1 | 2018 | 30 | 0.150 |
Why?
| | Vascular Diseases | 1 | 2021 | 244 | 0.150 |
Why?
| | Severity of Illness Index | 3 | 2025 | 2838 | 0.150 |
Why?
| | Blood Gas Analysis | 1 | 2018 | 74 | 0.140 |
Why?
| | Pandemics | 3 | 2022 | 1619 | 0.140 |
Why?
| | APACHE | 1 | 2018 | 69 | 0.140 |
Why?
| | Systemic Inflammatory Response Syndrome | 1 | 2018 | 95 | 0.140 |
Why?
| | Streptococcus | 1 | 2018 | 28 | 0.140 |
Why?
| | Endothelial Cells | 2 | 2016 | 780 | 0.140 |
Why?
| | Betacoronavirus | 1 | 2020 | 268 | 0.140 |
Why?
| | Female | 15 | 2025 | 73162 | 0.140 |
Why?
| | Precision Medicine | 1 | 2021 | 426 | 0.140 |
Why?
| | Cell Separation | 1 | 2018 | 320 | 0.130 |
Why?
| | Goals | 1 | 2018 | 168 | 0.130 |
Why?
| | Macrophage Activation | 1 | 2018 | 201 | 0.130 |
Why?
| | Adoptive Transfer | 3 | 2015 | 224 | 0.130 |
Why?
| | Disease Susceptibility | 1 | 2018 | 344 | 0.130 |
Why?
| | Soot | 1 | 2016 | 26 | 0.130 |
Why?
| | Colorado | 2 | 2024 | 4521 | 0.130 |
Why?
| | Research | 1 | 2019 | 446 | 0.120 |
Why?
| | Chemokines | 2 | 2015 | 229 | 0.120 |
Why?
| | Leukocytosis | 1 | 2015 | 31 | 0.120 |
Why?
| | DNA Modification Methylases | 1 | 2015 | 17 | 0.120 |
Why?
| | Pneumonia, Viral | 1 | 2020 | 368 | 0.120 |
Why?
| | Coronavirus Infections | 1 | 2020 | 359 | 0.120 |
Why?
| | Lung Transplantation | 1 | 2018 | 309 | 0.120 |
Why?
| | Muscular Atrophy | 2 | 2015 | 83 | 0.120 |
Why?
| | Wasting Syndrome | 1 | 2015 | 12 | 0.120 |
Why?
| | Nitric Oxide Synthase Type II | 2 | 2012 | 173 | 0.120 |
Why?
| | Retrospective Studies | 5 | 2024 | 15628 | 0.120 |
Why?
| | Epithelium | 1 | 2016 | 315 | 0.120 |
Why?
| | Interview, Psychological | 1 | 2015 | 98 | 0.110 |
Why?
| | Lipoprotein Lipase | 2 | 2013 | 59 | 0.110 |
Why?
| | Interleukin-10 | 2 | 2014 | 302 | 0.110 |
Why?
| | Tissue and Organ Procurement | 1 | 2018 | 314 | 0.110 |
Why?
| | Ubiquitin-Protein Ligases | 2 | 2015 | 179 | 0.110 |
Why?
| | Muscle Proteins | 2 | 2015 | 229 | 0.110 |
Why?
| | Societies, Medical | 1 | 2018 | 820 | 0.110 |
Why?
| | Diagnostic and Statistical Manual of Mental Disorders | 1 | 2015 | 243 | 0.110 |
Why?
| | Air Pollution, Indoor | 1 | 2016 | 179 | 0.110 |
Why?
| | Azacitidine | 1 | 2015 | 141 | 0.110 |
Why?
| | Cells, Cultured | 4 | 2016 | 4206 | 0.110 |
Why?
| | Particulate Matter | 1 | 2016 | 314 | 0.110 |
Why?
| | Lipoproteins | 2 | 2013 | 168 | 0.110 |
Why?
| | Osteomyelitis | 1 | 2015 | 137 | 0.100 |
Why?
| | Phenethylamines | 1 | 2013 | 23 | 0.100 |
Why?
| | Adenosine A2 Receptor Agonists | 1 | 2013 | 21 | 0.100 |
Why?
| | Forkhead Transcription Factors | 2 | 2015 | 191 | 0.100 |
Why?
| | Treatment Outcome | 6 | 2024 | 10821 | 0.100 |
Why?
| | Bacteremia | 1 | 2015 | 209 | 0.100 |
Why?
| | Gene Knockout Techniques | 1 | 2013 | 116 | 0.100 |
Why?
| | Aquaporin 5 | 1 | 2012 | 3 | 0.100 |
Why?
| | Adaptive Clinical Trials as Topic | 2 | 2022 | 22 | 0.100 |
Why?
| | United States | 8 | 2021 | 14696 | 0.100 |
Why?
| | Physical Conditioning, Animal | 1 | 2015 | 255 | 0.100 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 2 | 2016 | 974 | 0.100 |
Why?
| | Cyclic Nucleotide Phosphodiesterases, Type 2 | 1 | 2011 | 1 | 0.090 |
Why?
| | Enzyme Inhibitors | 1 | 2015 | 845 | 0.090 |
Why?
| | Adenosine | 1 | 2013 | 227 | 0.090 |
Why?
| | Time Factors | 5 | 2016 | 6817 | 0.090 |
Why?
| | Air Pollutants | 1 | 2016 | 428 | 0.090 |
Why?
| | Pulmonary Disease, Chronic Obstructive | 2 | 2016 | 1042 | 0.090 |
Why?
| | Capillary Permeability | 1 | 2011 | 144 | 0.090 |
Why?
| | Aftercare | 2 | 2023 | 210 | 0.090 |
Why?
| | Treatment Failure | 2 | 2022 | 353 | 0.090 |
Why?
| | Staphylococcal Infections | 1 | 2015 | 402 | 0.090 |
Why?
| | Exercise Therapy | 1 | 2015 | 435 | 0.080 |
Why?
| | Longitudinal Studies | 1 | 2018 | 2857 | 0.080 |
Why?
| | Family | 1 | 2015 | 667 | 0.080 |
Why?
| | Genes, RAG-1 | 1 | 2009 | 12 | 0.080 |
Why?
| | HIV-1 | 1 | 2016 | 863 | 0.080 |
Why?
| | Leukocyte Reduction Procedures | 1 | 2009 | 26 | 0.080 |
Why?
| | Hypertension, Pulmonary | 1 | 2021 | 1903 | 0.080 |
Why?
| | Microtubules | 1 | 2012 | 270 | 0.080 |
Why?
| | Interleukin-2 Receptor alpha Subunit | 1 | 2009 | 84 | 0.080 |
Why?
| | Monocytes | 1 | 2012 | 568 | 0.080 |
Why?
| | Biomarkers | 2 | 2018 | 4172 | 0.080 |
Why?
| | Leukocyte Count | 1 | 2009 | 331 | 0.080 |
Why?
| | Cluster Analysis | 1 | 2009 | 502 | 0.070 |
Why?
| | Heart Failure | 1 | 2021 | 2222 | 0.070 |
Why?
| | Oligonucleotide Array Sequence Analysis | 1 | 2009 | 765 | 0.070 |
Why?
| | Muscle, Skeletal | 2 | 2015 | 1701 | 0.070 |
Why?
| | Gene Regulatory Networks | 1 | 2009 | 308 | 0.070 |
Why?
| | Cohort Studies | 3 | 2024 | 5730 | 0.070 |
Why?
| | T-Lymphocyte Subsets | 1 | 2009 | 425 | 0.070 |
Why?
| | Adipose Tissue | 1 | 2011 | 624 | 0.070 |
Why?
| | Sleep Apnea, Obstructive | 1 | 2011 | 291 | 0.060 |
Why?
| | Mental Disorders | 1 | 2015 | 1083 | 0.060 |
Why?
| | Patient Discharge | 2 | 2023 | 895 | 0.060 |
Why?
| | Lymphocyte Count | 1 | 2025 | 150 | 0.060 |
Why?
| | Homeodomain Proteins | 3 | 2015 | 504 | 0.060 |
Why?
| | Receptors, CXCR4 | 2 | 2016 | 85 | 0.050 |
Why?
| | Gene Expression Regulation | 2 | 2012 | 2615 | 0.050 |
Why?
| | Renal Replacement Therapy | 1 | 2024 | 92 | 0.050 |
Why?
| | Masks | 1 | 2024 | 62 | 0.050 |
Why?
| | Tomography, X-Ray Computed | 2 | 2006 | 2681 | 0.050 |
Why?
| | Tripartite Motif Proteins | 2 | 2015 | 41 | 0.050 |
Why?
| | United States Food and Drug Administration | 1 | 2024 | 208 | 0.050 |
Why?
| | Infusions, Intravenous | 1 | 2024 | 411 | 0.050 |
Why?
| | Streptococcus pneumoniae | 1 | 2025 | 169 | 0.050 |
Why?
| | Sensitivity and Specificity | 3 | 2018 | 1950 | 0.050 |
Why?
| | CD4-Positive T-Lymphocytes | 1 | 2009 | 1092 | 0.050 |
Why?
| | Nucleocapsid | 1 | 2022 | 17 | 0.050 |
Why?
| | Angiopoietins | 2 | 2013 | 13 | 0.050 |
Why?
| | Clinical Trials, Phase II as Topic | 1 | 2022 | 75 | 0.050 |
Why?
| | Cell Line, Transformed | 2 | 2012 | 145 | 0.050 |
Why?
| | Electroencephalography | 1 | 2025 | 438 | 0.050 |
Why?
| | Hemoglobins | 1 | 2024 | 356 | 0.050 |
Why?
| | Epigenomics | 1 | 2022 | 115 | 0.050 |
Why?
| | Granulomatosis with Polyangiitis | 1 | 2002 | 44 | 0.050 |
Why?
| | Blotting, Western | 2 | 2016 | 1227 | 0.050 |
Why?
| | National Institutes of Health (U.S.) | 1 | 2021 | 129 | 0.040 |
Why?
| | HIV Infections | 1 | 2016 | 2830 | 0.040 |
Why?
| | Health Policy | 1 | 2024 | 388 | 0.040 |
Why?
| | Multicenter Studies as Topic | 1 | 2022 | 308 | 0.040 |
Why?
| | Random Allocation | 2 | 2012 | 357 | 0.040 |
Why?
| | Macrophages, Peritoneal | 2 | 2012 | 94 | 0.040 |
Why?
| | User-Computer Interface | 1 | 2002 | 159 | 0.040 |
Why?
| | Review Literature as Topic | 1 | 2021 | 74 | 0.040 |
Why?
| | Bronchoscopy | 1 | 2002 | 222 | 0.040 |
Why?
| | Drug Discovery | 1 | 2021 | 141 | 0.040 |
Why?
| | Phenotype | 2 | 2022 | 3205 | 0.040 |
Why?
| | Antimalarials | 1 | 2020 | 32 | 0.040 |
Why?
| | Heart Arrest | 1 | 2024 | 339 | 0.040 |
Why?
| | Prospective Studies | 3 | 2023 | 7598 | 0.040 |
Why?
| | Bayes Theorem | 1 | 2022 | 407 | 0.040 |
Why?
| | Airway Obstruction | 1 | 2002 | 162 | 0.040 |
Why?
| | Single-Blind Method | 1 | 2020 | 288 | 0.040 |
Why?
| | Double-Blind Method | 1 | 2024 | 1987 | 0.040 |
Why?
| | Netherlands | 1 | 2018 | 88 | 0.040 |
Why?
| | Sleep | 1 | 2025 | 754 | 0.040 |
Why?
| | Ventricular Dysfunction, Right | 1 | 2021 | 236 | 0.040 |
Why?
| | Clinical Trials as Topic | 1 | 2022 | 1047 | 0.030 |
Why?
| | Epigenesis, Genetic | 1 | 2022 | 660 | 0.030 |
Why?
| | Inflammation | 3 | 2015 | 2837 | 0.030 |
Why?
| | Image Processing, Computer-Assisted | 1 | 2002 | 784 | 0.030 |
Why?
| | ROC Curve | 1 | 2018 | 547 | 0.030 |
Why?
| | Congresses as Topic | 1 | 2018 | 233 | 0.030 |
Why?
| | Electronic Health Records | 1 | 2024 | 1040 | 0.030 |
Why?
| | Computational Biology | 1 | 2021 | 645 | 0.030 |
Why?
| | Risk Factors | 2 | 2022 | 10356 | 0.030 |
Why?
| | Bacterial Infections | 1 | 2018 | 251 | 0.030 |
Why?
| | Cognition | 1 | 2024 | 1192 | 0.030 |
Why?
| | Dose-Response Relationship, Drug | 1 | 2020 | 2066 | 0.030 |
Why?
| | Virus Diseases | 1 | 2018 | 217 | 0.030 |
Why?
| | Cell Count | 1 | 2016 | 321 | 0.030 |
Why?
| | Intercellular Adhesion Molecule-1 | 1 | 2016 | 139 | 0.030 |
Why?
| | Graft Survival | 1 | 2018 | 540 | 0.030 |
Why?
| | Cooperative Behavior | 1 | 2018 | 447 | 0.030 |
Why?
| | Receptors, Granulocyte Colony-Stimulating Factor | 1 | 2015 | 1 | 0.030 |
Why?
| | Ethnopsychology | 1 | 2015 | 5 | 0.030 |
Why?
| | Extracellular Signal-Regulated MAP Kinases | 1 | 2016 | 170 | 0.030 |
Why?
| | Granulocyte Colony-Stimulating Factor | 1 | 2015 | 74 | 0.030 |
Why?
| | Chemotaxis, Leukocyte | 1 | 2015 | 138 | 0.030 |
Why?
| | Microscopy, Confocal | 1 | 2016 | 327 | 0.030 |
Why?
| | Cross-Cultural Comparison | 1 | 2015 | 93 | 0.030 |
Why?
| | Cadherins | 1 | 2016 | 205 | 0.030 |
Why?
| | Respiratory Function Tests | 1 | 2016 | 596 | 0.030 |
Why?
| | Sputum | 1 | 2016 | 311 | 0.030 |
Why?
| | Cell Lineage | 1 | 2016 | 346 | 0.030 |
Why?
| | Diagnosis, Differential | 1 | 2018 | 1486 | 0.030 |
Why?
| | Immunocompromised Host | 1 | 2015 | 203 | 0.030 |
Why?
| | Influenza A Virus, H1N1 Subtype | 1 | 2015 | 152 | 0.030 |
Why?
| | Environmental Monitoring | 1 | 2016 | 371 | 0.030 |
Why?
| | Magnetic Resonance Imaging | 1 | 2006 | 3722 | 0.030 |
Why?
| | Adipose Tissue, White | 1 | 2013 | 40 | 0.030 |
Why?
| | Benzylamines | 1 | 2012 | 41 | 0.020 |
Why?
| | Mice, Congenic | 1 | 2012 | 23 | 0.020 |
Why?
| | B7-2 Antigen | 1 | 2012 | 27 | 0.020 |
Why?
| | Host-Pathogen Interactions | 1 | 2016 | 367 | 0.020 |
Why?
| | Heterocyclic Compounds | 1 | 2012 | 20 | 0.020 |
Why?
| | Adipose Tissue, Brown | 1 | 2013 | 52 | 0.020 |
Why?
| | Cell Survival | 1 | 2016 | 1122 | 0.020 |
Why?
| | Chemokine CXCL12 | 1 | 2012 | 80 | 0.020 |
Why?
| | RING Finger Domains | 1 | 2012 | 4 | 0.020 |
Why?
| | Diet, Atherogenic | 1 | 2011 | 6 | 0.020 |
Why?
| | Chylomicrons | 1 | 2011 | 9 | 0.020 |
Why?
| | Lipoproteins, VLDL | 1 | 2011 | 18 | 0.020 |
Why?
| | Ventilators, Mechanical | 1 | 2011 | 58 | 0.020 |
Why?
| | Myofibroblasts | 1 | 2012 | 125 | 0.020 |
Why?
| | Cyclic GMP | 1 | 2011 | 94 | 0.020 |
Why?
| | Cross-Sectional Studies | 1 | 2022 | 5427 | 0.020 |
Why?
| | Quality of Life | 1 | 2023 | 2870 | 0.020 |
Why?
| | Gene Expression | 1 | 2016 | 1505 | 0.020 |
Why?
| | Ventilator-Induced Lung Injury | 1 | 2011 | 59 | 0.020 |
Why?
| | Adenoviridae | 1 | 2011 | 193 | 0.020 |
Why?
| | Cyclic AMP | 1 | 2011 | 243 | 0.020 |
Why?
| | Motor Activity | 1 | 2015 | 723 | 0.020 |
Why?
| | Trachea | 1 | 2011 | 236 | 0.020 |
Why?
| | Down-Regulation | 1 | 2012 | 658 | 0.020 |
Why?
| | Obesity | 1 | 2022 | 2974 | 0.020 |
Why?
| | Muscle Strength | 1 | 2012 | 315 | 0.020 |
Why?
| | Risk Assessment | 1 | 2018 | 3439 | 0.020 |
Why?
| | Vascular Endothelial Growth Factor A | 1 | 2011 | 544 | 0.020 |
Why?
| | RNA, Small Interfering | 1 | 2011 | 621 | 0.020 |
Why?
| | Cardiovascular Diseases | 1 | 2021 | 2113 | 0.020 |
Why?
| | Multivariate Analysis | 1 | 2012 | 1524 | 0.020 |
Why?
| | Young Adult | 1 | 2024 | 13243 | 0.020 |
Why?
| | Immunohistochemistry | 1 | 2012 | 1740 | 0.020 |
Why?
| | Fibroblasts | 1 | 2012 | 990 | 0.020 |
Why?
| | Cell Line | 1 | 2012 | 2852 | 0.020 |
Why?
| | Postoperative Complications | 1 | 2018 | 2641 | 0.020 |
Why?
| | Aged, 80 and over | 1 | 2018 | 7593 | 0.020 |
Why?
| | Anti-Bacterial Agents | 1 | 2015 | 1800 | 0.010 |
Why?
| | Adolescent | 1 | 2024 | 21555 | 0.010 |
Why?
| | Proteins | 1 | 2011 | 1012 | 0.010 |
Why?
| | Cell Proliferation | 1 | 2012 | 2482 | 0.010 |
Why?
| | Survival Rate | 1 | 2009 | 1980 | 0.010 |
Why?
| | RNA, Messenger | 1 | 2011 | 2838 | 0.010 |
Why?
| | Randomized Controlled Trials as Topic | 1 | 2009 | 1465 | 0.010 |
Why?
| | Bronchography | 1 | 2002 | 10 | 0.010 |
Why?
| | Tracheal Stenosis | 1 | 2002 | 31 | 0.010 |
Why?
| | Blood Glucose | 1 | 2011 | 2183 | 0.010 |
Why?
| | Observer Variation | 1 | 2002 | 347 | 0.010 |
Why?
| | Insulin | 1 | 2011 | 2398 | 0.010 |
Why?
| | Signal Transduction | 1 | 2012 | 5096 | 0.010 |
Why?
|
|
Aggarwal's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|